These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26894823)

  • 41. Psychopharmacology of the Rage Attack Phenomenon in a Child with Obsessive Compulsive Disorder.
    Weiss-Goldman N; Arditi B; Rice T; Coffey BJ
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):360-362. PubMed ID: 29889566
    [No Abstract]   [Full Text] [Related]  

  • 42. A thorough QT study of guanfacine.
    Martin P; Satin L; Kahn RS; Robinson A; Corcoran M; Purkayastha J; Youcha S; Ermer JC
    Int J Clin Pharmacol Ther; 2015 Apr; 53(4):301-16. PubMed ID: 25109412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stimulation of postsynapse adrenergic α2A receptor improves attention/cognition performance in an animal model of attention deficit hyperactivity disorder.
    Kawaura K; Karasawa J; Chaki S; Hikichi H
    Behav Brain Res; 2014 Aug; 270():349-56. PubMed ID: 24882610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.
    Verplaetse TL; Roberts W; Moore KE; Peltier MR; Oberleitner LM; McKee SA
    J Clin Psychopharmacol; 2019; 39(2):124-128. PubMed ID: 30707118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prolonged bradycardia and hypotension following guanfacine extended release overdose.
    Walton J; Byrum M; Shumaker A; Coury DL
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):463-5. PubMed ID: 25010857
    [No Abstract]   [Full Text] [Related]  

  • 46. Guanfacine in children with autism and/or intellectual disabilities.
    Handen BL; Sahl R; Hardan AY
    J Dev Behav Pediatr; 2008 Aug; 29(4):303-8. PubMed ID: 18552703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine].
    Martin Fernandez-Mayoralas D; Fernandez-Perrone AL; Munoz-Jareno N; Fernandez-Jaen A
    Rev Neurol; 2017 Mar; 64(s02):S1-S8. PubMed ID: 28272733
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Enteral Guanfacine to Treat Severe Anxiety and Agitation Complicating Critical Care After Cardiac Surgery.
    Srour H; Pandya K; Flannery A; Hatton K
    Semin Cardiothorac Vasc Anesth; 2018 Dec; 22(4):403-406. PubMed ID: 29619866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder.
    Scahill L; Chappell PB; Kim YS; Schultz RT; Katsovich L; Shepherd E; Arnsten AF; Cohen DJ; Leckman JF
    Am J Psychiatry; 2001 Jul; 158(7):1067-74. PubMed ID: 11431228
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine).
    Mattes JA
    J Am Acad Psychiatry Law; 2016 Jun; 44(2):151-7. PubMed ID: 27236168
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Guanfacine use in children with attention deficit hyperactivity disorder.
    Cohn LM; Caliendo GC
    Ann Pharmacother; 1997; 31(7-8):918-9. PubMed ID: 9220058
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE; Bukstein O; Brams M; Cutler AJ; Childress A; Rugino T; Lyne A; Grannis K; Youcha S
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prospective open trial of guanfacine in children with pervasive developmental disorders.
    Scahill L; Aman MG; McDougle CJ; McCracken JT; Tierney E; Dziura J; Arnold LE; Posey D; Young C; Shah B; Ghuman J; Ritz L; Vitiello B
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):589-98. PubMed ID: 17069547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Guanfacine and secondary mania in children.
    Horrigan JP; Barnhill LJ
    J Affect Disord; 1999 Aug; 54(3):309-14. PubMed ID: 10467976
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neurocognitive dysfunction and pharmacological intervention using guanfacine in a rhesus macaque model of self-injurious behavior.
    Freeman ZT; Rice KA; Soto PL; Pate KA; Weed MR; Ator NA; DeLeon IG; Wong DF; Zhou Y; Mankowski JL; Zink MC; Adams RJ; Hutchinson EK
    Transl Psychiatry; 2015 May; 5(5):e567. PubMed ID: 25989141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Sallee FR; Lyne A; Wigal T; McGough JJ
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):215-26. PubMed ID: 19519256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D; Pennick M; Shojaei A; Lyne A; Fiske K
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Growth hormone response to guanfacine in boys with attention deficit hyperactivity disorder: a preliminary study.
    Halperin JM; Newcorn JH; McKay KE; Siever LJ; Sharma V
    J Child Adolesc Psychopharmacol; 2003; 13(3):283-94. PubMed ID: 14642016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.